Paragon Therapeutics & Schall Brown & Schwartz LLP
2 shared events · Importance 4 · Last updated Sep 08, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Schall Brown & Schwartz LLP: Filed a class action lawsuit against Capricor.
Jul 27, 2026 · 305 articles
Regulatory
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Schall Brown & Schwartz LLP: The firm reminded investors of the class action and the September 28, 2026 lead plaintiff deadline.
Aug 10, 2026 · 267 articles
100
Schall Brown & Schwartz LLP filed class action Paragon TherapeuticsCapricor Deramiocel...
95
Schall Brown & Schwartz LLP filed class action Paragon TherapeuticsCapricor Deramiocel...
90
Schall Brown & Schwartz LLP filed class action lawsuit Paragon TherapeuticsCapricor Deramiocel...
85
Schall Brown & Schwartz LLP filed class action Paragon TherapeuticsCapricor Deramiocel...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Paragon Therapeutics and Schall Brown & Schwartz LLP interact across events, view sentiment trends, and discover connected entities.
Open Dashboard